NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
20 Setembro 2023 - 9:00AM
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam
Pharma” or the “Company”), a clinical-stage biopharmaceutical
company developing oral, non-statin medicines for patients at high
risk of cardiovascular disease with residual elevation of
low-density lipoprotein cholesterol (“LDL-C”), for whom existing
therapies are not sufficiently effective or well-tolerated, today
announced that Michael Davidson, M.D., chief executive officer of
NewAmsterdam Pharma, will participate in a fireside chat at the
2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday,
September 27, 2023 at 1:50 p.m. ET.
A live webcast of the fireside chat will be available through
the investor relations section of the NewAmsterdam Pharma website
at ir.newamsterdampharma.com. Following the live webcast, an
archived replay will be available on the Company’s website.
About NewAmsterdam
Based in the Netherlands, NewAmsterdam (Nasdaq: NAMS) is a
clinical-stage biopharmaceutical company whose mission is to
improve patient care in populations with metabolic diseases where
currently approved therapies have not been sufficiently adequate or
well tolerated. We seek to fill a significant unmet need for a
safe, cost-effective and convenient LDL-lowering therapy as an
adjunct to statins, a class of lipid-lowering medications that are
the current standard of care for high-risk CVD patients with high
cholesterol. NewAmsterdam is investigating obicetrapib, an oral,
low-dose and once-daily CETP inhibitor, as the preferred LDL-C
lowering therapy to be used as an adjunct to maximally tolerated
statin therapy for high-risk cardiovascular disease patients.
Company Contact
Matthew PhilippeP:
917-882-7512matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdamJenn GordonP:
1-202-957-7795jgordon@spectrumscience.com
Investor Contact
Stern Investor Relations on behalf of NewAmsterdamHannah
DeresiewiczP: 1 212-362-1200hannah.deresiewicz@sternir.com
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024